Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
4.350
-0.450 (-9.38%)
At close: Feb 21, 2025, 4:00 PM
4.460
+0.110 (2.53%)
After-hours: Feb 21, 2025, 7:50 PM EST
Windtree Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
782.11K
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
WINT News
- 5 weeks ago - Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline - GlobeNewsWire
- 5 weeks ago - Windtree Announces the Addition of Leanne Kelly to Its Board of Directors - GlobeNewsWire
- 2 months ago - Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia - GlobeNewsWire
- 2 months ago - Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction - GlobeNewsWire
- 3 months ago - Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates - GlobeNewsWire
- 4 months ago - Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World - GlobeNewsWire
- 4 months ago - Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan - GlobeNewsWire
- 5 months ago - Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock - GlobeNewsWire